Skip to main content

Table 4 Urinary symptoms improvement after switching from tolterodine ER to fesoterodine according to fesoterodine dose at the study visit

From: Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study

Urinary symptom
(not at all = 0 to quite a lot = 5)
Total 4 mg 8 mg p value between groups
Worry     
 Frequency 3.2 (3.1-3.3) 3.4 (3.3-3.5) 3.1 (3.0-3.2) 0.001
 Incontinence during sexual attempt 2.2 (2.2-2.3) 2.1 (1.9-2.2) 2.2 (2.1-2.4) 0.075
 Nocturia 3.0 (2.9-3.1) 3.2 (3.1-3.4) 3.0 (2.9-3.1) 0.010
 Frequency of infections 2.4 (2.3-2.5) 2.4 (2.2-2.5) 2.4 (2.3-2.5) 0.812
 Urgency 3.2 (3.1-3.3) 3.4 (3.2-3.5) 3.2 (3.1-3.3) 0.026
 Bladder pain 2.3 (2.3-2.4) 2.4 (2.3-2.6) 2.3 (2.2-2.4) 0.207
 Urge incontinence 3.1 (3.0-3.3) 3.3 (3.2-3.5) 3.1 (3.0-3.2) 0.008
 Urinary difficulties 2.2 (2.1-2.3) 2.2 (2.0-2.3) 2.2 (2.1-2.3) 0.691
 Stress incontinence 2.2 (2.1-2.3) 2.1 (1.9-2.3) 2.2 (2.1-2.3) 0.304
Bother     
 Urinary frequency 3.2 (3.2-3.3) 3.4 (3.3-3.6) 3.2 (3.1-3.2) 0.001
 Strong desire to urinate 3.3 (3.2-3.4) 3.5 (3.4-3.7) 3.2 (3.1-3.3) <0.001
 Urine loss associated with a strong desire to urinate 3.1 (3.0-3.2) 3.3 (3.1-3.5) 3.0 (2.9-3.1) 0.007
Interference with daily-living activities    
 Usual activities 3.0 (2.9-3.1) 3.1 (3.0-3.3) 3.0 (2.9-3.1) 0.119
 Leisure 3.1 (3.0-3.2) 3.2 (3.1-3.4) 3.0 (2.9-3.1) 0.032
 Work/domestic activities 2.5 (2.4-2.6) 2.5 (2.3-2.6) 2.4 (2.3-2.5) 0.717
  1. p significance level adjusted by sex, driven of treatment change, treatment adherence, treatment length, reason for switching; Values are mean (95% Confidence Interval).